Filing history

Beijing Tinavi Medical Technology— every filing summary in full, newest first. The status card's three-section read is synthesized from exactly these.

Synthesized read · Sep 28, 2026

Where it standsAs of 2025-12-31, 688277.SH (TINAVI Medical Technologies) is a loss-making MedTech with revenue of CNY 278.8m and a gross margin near 69%. However, EBITDA is negative at CNY -154.6m and net income is CNY -196.1m. The balance sheet shows CNY 264.2m cash against CNY 193.7m total debt, resulting in net cash of CNY 70.4m and a net leverage ratio of roughly 0.46x (net debt/EBITDA) — well below the 2.5x threshold. Book-to-bill and backlog are not provided. No EDGAR filings were detected. Recent signals point to a pending asset acquisition via share issuance and related-party transaction, which could dilute existing shareholders, but no current rule directly captures this event. If net loss is used as a proxy for cash burn, runway is approximately 16 months, but the cash runway rule applies only to pre-revenue Pharma names, not this MedTech. No rule-based flags fired.

Full timeline · 32 filings · 0 with a parsed narrative

No qualitative filing summaries are parsed for this market yet — the timeline below lists the filings on record, but the narrative fields are US/HK-only for now.

OTHER2026-09-27
Source ↗
No parsed narrative for this filing.
OTHER2026-09-27
Source ↗
No parsed narrative for this filing.
OTHER2026-09-09
Source ↗
No parsed narrative for this filing.
OTHER2026-09-07
Source ↗
No parsed narrative for this filing.
OTHER2026-09-07
Source ↗
No parsed narrative for this filing.
OTHER2026-09-07
Source ↗
No parsed narrative for this filing.
OTHER2026-09-07
Source ↗
No parsed narrative for this filing.
OTHER2026-09-07
Source ↗
No parsed narrative for this filing.
OTHER2026-09-07
Source ↗
No parsed narrative for this filing.
OTHER2026-09-07
Source ↗
No parsed narrative for this filing.
OTHER2026-09-07
Source ↗
No parsed narrative for this filing.
OTHER2026-09-07
Source ↗
No parsed narrative for this filing.
OTHER2026-09-07
Source ↗
No parsed narrative for this filing.
OTHER2026-09-04
Source ↗
No parsed narrative for this filing.
OTHER2026-08-28
Source ↗
No parsed narrative for this filing.
OTHER2026-08-25
Source ↗
No parsed narrative for this filing.
OTHER2026-08-25
Source ↗
No parsed narrative for this filing.
OTHER2026-08-25
Source ↗
No parsed narrative for this filing.
OTHER2026-08-25
Source ↗
No parsed narrative for this filing.
OTHER2026-08-25
Source ↗
No parsed narrative for this filing.
OTHER2026-08-06
Source ↗
No parsed narrative for this filing.
OTHER2026-07-29
Source ↗
No parsed narrative for this filing.
OTHER2026-07-29
Source ↗
No parsed narrative for this filing.
OTHER2026-07-29
Source ↗
No parsed narrative for this filing.
OTHER2026-07-29
Source ↗
No parsed narrative for this filing.
OTHER2026-07-29
Source ↗
No parsed narrative for this filing.
OTHER2026-07-29
Source ↗
No parsed narrative for this filing.
OTHER2026-07-29
Source ↗
No parsed narrative for this filing.
OTHER2026-07-29
Source ↗
No parsed narrative for this filing.
OTHER2026-07-29
Source ↗
No parsed narrative for this filing.
OTHER2026-07-29
Source ↗
No parsed narrative for this filing.
OTHER2026-07-29
Source ↗
No parsed narrative for this filing.

Extracted facts only — this page reproduces the stored filing summaries; it computes no valuation. Not investment advice.